News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
Aesica Appoints Chris Gowland to the Board in Newly Created Position of Group Chief Operating Officer
7/29/2013 8:04:40 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
29 July 2013: Aesica, the global contract development and manufacturing organisation (CDMO), has appointed Chris Gowland to the newly formed position of Chief Operating Officer.
As COO, Gowland has overall responsibility for all operating strategy. He leads international operational delivery, continuing to guarantee best in class on time in full (OTIF) services across the Aesica Group.
His remit encompasses the setting of operational standards and driving continuous improvement across the company’s manufacturing capabilities in API and Formulated Products. Gowland is now responsible for operational performance and general management of all Aesica manufacturing sites including Queenborough and Cramlington in the UK, Monheim and Zwickau in Germany and Pianezza in Italy.
Under the new structure, Steve Barker, and Jarrett Palmer, Operations Directors for the API and Formulated Products business units respectively will report directly to the COO.
Gowland’s responsibilities also include the management of capital expenditure, procurement of materials and services, managing the supply chain and overseeing capacity expansion across the Group to ensure that Aesica meets full customer demand whilst delivering maximum service value.
Commenting on his role as COO, Chris Gowland remarked: “I am delighted to have the opportunity to lead a manufacturing structure in which I am responsible for driving highly efficient operational delivery and the highest standards of operational excellence across Aesica internationally.”
He continued: “Indeed the role is heavily directed at ensuring maximum value to our customers through the effective management of the Aesica supply chain. My intention is to delight our customers through fast, flexible and efficient product delivery to support their market needs and product development.”
Aesica supplies contract development and contract manufacturing services for Formulated Products and Active Pharmaceutical Ingredients to a host of the world’s leading pharmaceutical companies and emerging biotechnology organisations.
The uniqueness of Aesica lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. It is this all-encompassing offering combined with its dedication to exceptional standards of service that truly sets Aesica apart from its counterparts.
- Aesica is one of the UK’s fastest growing companies and over the last five years has more than trebled its turnover.
- The company currently employs approximately 1,300 people.
- In addition to its headquarters in Newcastle upon Tyne, UK, Aesica has development and manufacturing sites across Europe including Cramlington, Nottingham and Queenborough in the UK, as well as sites in Monheim and Zwickau in Germany and Pianezza in Italy. It also has sales representation in San Diego and Shanghai.
- The vision of Aesica is to become the number one supplier of APIs and formulated products to the pharmaceutical industry.
For media enquiries, please contact Alex Heeley or Tristan Jervis at De Facto Communications on: +44 (0) 20 7203 6740 or e-mail; email@example.com.
Help employers find you! Check out all the jobs and post your resume.